Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

Core Insights - Inhibikase Therapeutics is expanding its therapeutic pipeline with multiple late-stage development assets targeting Parkinson's disease and related disorders [1][2] - The company anticipates completing the 201 Trial for untreated Parkinson's disease by the end of Q3 2024, with 94% enrollment achieved [2][5] - Inhibikase is redirecting efforts for IkT-001Pro into cardiopulmonary disease, specifically targeting Pulmonary Arterial Hypertension (PAH) [2][5] Company Updates - The company has initiated clinical development of its product candidates since 2021 and expects to have multiple late-stage ready assets by 2025 [2] - The 201 Trial is expected to report biomarker and outcome data to support discussions with the FDA for End of Phase 2 and Phase 3 protocols by the end of 2024 [5] - Inhibikase is seeking grant funding for the 202 Trial in Multiple System Atrophy through the National Institute of Neurological Diseases and Stroke (NINDS) [5] Strategic Developments - Following a pre-IND meeting with the FDA, Inhibikase plans to submit an IND application for IkT-001Pro for PAH early in Q3 2024 [5] - The company is scaling manufacturing processes for IkT-001Pro to support late-stage clinical development and NDA batch requirements [5] - Inhibikase will discontinue development of treatments for Progressive Multifocal Leukoencephalopathy (PML) to focus on late-stage clinical assets in neurodegeneration, cancer, and cardiopulmonary disease [5]